Searching for the physiological role of glucose-dependent insulinotropic polypeptide

Journal of Diabetes Investigation

Volumn 7, Issue , 2016, Pages 8-12

  Holst, Jens Juul ^a   Windeløv, Johanne Agerlin ^a   Boer, Geke Aline ^a   Pedersen, Jens ^a   Svendsen, Berit ^a   Christensen, Mikkel ^a   Torekov, Signe ^a   Asmar, Meena ^a   Hartmann, Bolette ^a   Nissen, Anne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bone remodeling; Glucagon; Lipid metabolism

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR;

ARTICLE; BONE GROWTH; BONE METABOLISM; BONE TURNOVER; DIET INDUCED OBESITY; FRACTURE; GLUCAGON RELEASE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; INSULIN RELEASE; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; LOSS OF FUNCTION MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BONE; ENTEROENDOCRINE CELL; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; BONE AND BONES; DIABETES MELLITUS, TYPE 2; ENTEROENDOCRINE CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; HUMANS; LIPID METABOLISM; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84963538091     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12488     Document Type: Article

References (39)

1. Brown JC. Gastric inhibitory polypeptide. Monogr Endocrinol 1982; 24: III-XI, 1-88:III-88.
2. Holst JJ, Jensen SL, Knuhtsen S, et al. Effect of vagus, gastric inhibitory polypeptide, and HCl on gastrin and somatostatin release from perfused pig antrum. Am J Physiol 1983; 244: G515-G522.
3. Maxwell V, Shulkes A, Brown JC, et al. Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. Dig Dis Sci 1980; 25: 113-116.
4. Dupre J, Ross SA, Watson D, et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828.
5. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988; 9: 122-134.
6. Andersen DK, Elahi D, Brown JC, et al. Oral glucose augmentation of insulin secretion: interactions of gastric inhibitory polypeptide with ambient glucose and insuln levels. J Clin Invest 1978; 49: 152-161.
7. Vilsboll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121.
8. Hojberg PV, Zander M, Vilsboll T, et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 2008; 51: 632-640.
9. Vilsboll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 2003; 88: 4897-4903.
10. Christensen M, Vedtofte L, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 3103-3109.
11. Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol 2016; 78: 277-299.
12. Egerod KL, Engelstoft MS, Grunddal KV, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 2012; 153: 5782-5795.
13. Svendsen B, Pedersen J, Jacob Wewer AN, et al. An analysis of co-secretion and co-expression of gut hormones from male rat proximal and distal small intestine. Endocrinology 2015; 156: 847-857.
14. Svendsen B, Pais R, Engelstoft MS, et al. GLP1 and GIP cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness. J Endocrinol 2016; 228: 39-48.
15. Knop FK, Vilsboll T, Madsbad S, et al. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797-805.
16. Lund A, Vilsboll T, Bagger JI, et al. The separate and combined impact of the intestinal hormones, GIP, GLP-1 and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011; 300: E1038- E1046.
17. Lund A, Bagger JI, Christensen M, et al. Hyperglucagonemia after oral glucose and suppression of glucagon following intravenous glucose in totally pancreatectomized patients. Diabetes 2015; 64(Suppl. 1): A62-A63.
18. Bagger JI, Knop FK, Lund A, et al. Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia 2014; 57: 1720-1725.
19. Dirksen C, Bojsen-Moller KN, Jorgensen NB, et al. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia 2013; 56: 2679-2687.
20. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103.
21. Dawson JM, Greathead HM, Sessions VA, et al. Effect of gastric inhibitory polypeptide on bovine fat metabolism. Comp Biochem Physiol B Biochem Mol Biol 1999; 123: 79-88.
22. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
23. Ugleholdt R, Pedersen J, Bassi MR, et al. Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J Biol Chem 2011; 286: 44632-44645.
24. Pedersen J, Ugleholdt RK, Jorgensen SM, et al. Glucose-metabolism is altered after loss of L- and alpha-cells, but not influenced by loss of K-cells. Am J Physiol Endocrinol Metab 2013; 304: E60-E73.
25. Asmar M, Tangaa W, Madsbad S, et al. On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 2010; 298: E614-E621.
26. Asmar M, Simonsen L, Madsbad S, et al. GIP may enhance fatty acid re-esterification in subcutaneous, abdominal adipose tissue in lean humans. Diabetes 2010; 59: 2160-2163.
27. Asmar M, Simonsen L, Arngrim N, et al. Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int J Obes (Lond) 2014; 38: 259-265.
28. Moller CL, Vistisen D, Faerch K, et al. Glucose-dependent insulinotropic polypeptide (GIP) is associated with lower LDL but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study. J Clin Endocrinol Metab 2016; 201: 485-493 jc20153133.
29. Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141: 1228-1235.
30. Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007; 292: E543-E548.
31. Xie D, Cheng H, Hamrick M, et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005; 37: 759-769.
32. Morawska D, Sieklucka-Dziuba M, Kleinrok Z. Central action of glucagon. Pol J Pharmacol 1998; 50: 125-133.
33. Tsukiyama K, Yamada Y, Yamada C, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006; 20: 1644-1651.
34. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18: 2180-2189.
35. Nissen A, Christensen M, Knop FK, et al. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 2014; 99: E2325-E2329.
36. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833-842.
37. Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34: 140-147.
38. Torekov SS, Harslof T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 2014; 99: E729-E733.
39. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148.